Compare Amphastar Pharmaceuticals Inc (AMPH) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

XLK, the Technology Select Sector SPDR ETF, trades at $185.79, up 0.24% today, with a bullish technical signal driven by moving averages. It has gained 33% year-to-date as of July 2026, outperforming the Nasdaq-100, supported by strong tech earnings and sector inflows. A dividend of $0.23 is scheduled for June 2026.

The outlook remains positive given robust tech fundamentals and institutional optimism, but risks include market concentration, Fed policy shifts, and potential valuation pressures. Wall Street sentiment is bullish, though some investors are reducing mega-cap tech exposure ahead of key guidance updates.